HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia.

Abstract
Opioids represent effective drugs for the relief of pain, yet chronic opioid use often leads to a state of increased sensitivity to pain that is exacerbated during withdrawal. A sensitization of pain-related negative affect has been hypothesized to closely interact with addiction mechanisms. Neuro-adaptive changes occur as a consequence of excessive opioid exposure, including a recruitment of corticotropin-releasing factor (CRF) and norepinephrine (NE) brain stress systems. To better understand the mechanisms underlying the transition to dependence, we determined the effects of functional antagonism within these two systems on hyperalgesia-like behavior during heroin withdrawal utilizing models of both acute and chronic dependence. We found that passive or self-administered heroin produced a significant mechanical hypersensitivity. During acute opioid dependence, systemic administration of the CRF1 receptor antagonist MPZP (20 mg/kg) alleviated withdrawal-induced mechanical hypersensitivity. In contrast, several functional adrenergic system antagonists (clonidine, prazosin, propranolol) failed to alter mechanical hypersensitivity in this state. We then determined the effects of chronic MPZP or clonidine treatment on extended access heroin self-administration and found that MPZP, but not clonidine, attenuated escalation of heroin intake, whereas both drugs alleviated chronic dependence-associated hyperalgesia. These findings suggest that an early potentiation of CRF signaling occurs following opioid exposure that begins to drive both opioid-induced hyperalgesia and eventually intake escalation.
AuthorsPaula E Park, Joel E Schlosburg, Leandro F Vendruscolo, Gery Schulteis, Scott Edwards, George F Koob
JournalAddiction biology (Addict Biol) Vol. 20 Issue 2 Pg. 275-84 (Mar 2015) ISSN: 1369-1600 [Electronic] United States
PMID24330252 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright© 2013 Society for the Study of Addiction.
Chemical References
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-2 Receptor Agonists
  • Adrenergic beta-Antagonists
  • N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-amine
  • Narcotics
  • Pyrimidines
  • Receptors, Corticotropin-Releasing Hormone
  • CRF receptor type 1
  • Heroin
  • Propranolol
  • Clonidine
  • Prazosin
Topics
  • Adrenergic alpha-1 Receptor Antagonists (pharmacology)
  • Adrenergic alpha-2 Receptor Agonists (pharmacology)
  • Adrenergic beta-Antagonists (pharmacology)
  • Animals
  • Behavior, Animal (drug effects)
  • Clonidine (pharmacology)
  • Drug-Seeking Behavior (drug effects)
  • Heroin (administration & dosage)
  • Heroin Dependence (metabolism)
  • Hyperalgesia (metabolism)
  • Narcotics (administration & dosage)
  • Prazosin (pharmacology)
  • Propranolol (pharmacology)
  • Pyrimidines (pharmacology)
  • Rats
  • Receptors, Corticotropin-Releasing Hormone (antagonists & inhibitors, metabolism)
  • Self Administration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: